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doi:10.1Objective: Prolonged aortic crossclamping can increase mortality and morbidity after aortic valve replacement
in elderly and high-risk patients. Sutureless implantation of the prosthesis has the potential to shorten aortic
crossclamp time.
Methods: The Perceval S valve (Sorin Biomedica Cardio Srl, Sallugia, Italy), a sutureless implantable aortic
bioprosthesis, was used in 32 patients (median age, 78 years; median logistic euroSCORE, 9.99) requiring aortic
valve replacement with or without concomitant coronary artery bypass grafting. Hemodynamic parameters and
clinical outcome were obtained at discharge, at 6 months, and up to 1 year postoperatively.
Results: Aortic crossclamp time needed for aortic valve replacement was 18 6 minutes. Hemodynamics at dis-
charge showed good function of all Perceval S valves with low transvalvular pressure gradients (mean, 12 5 mm
Hg and peak, 23 9 mmHg) and low incidence of paravalvular or valvular leakage. Operative mortality was 0%.
Follow-up at 1 year showed 3 non–valve-related deaths. Survivors showed good clinical outcome and stable hemo-
dynamic function of the valve prosthesis, except for 1 patient in whom endocarditis developed. Despite a moderate
decrease in platelet counts persisting up to 12months, freedom of bleeding and thromboembolic events was 100%.
Conclusions: It is possible to implant a well-functioning sutureless stent-mounted valve in the aortic position in
less than 20 minutes of aortic crossclamping. This is associated with excellent early clinical and hemodynamic
outcome in high-risk patients. Moderate changes in hematologic parameters persisted but were not related to
clinical events. (J Thorac Cardiovasc Surg 2011;142:1453-7)A
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DVideo clip is available online.
In Europe, it was recently suggested that approximately one
third of patients aged more than 75 years with valvular heart
disease do not undergo surgical aortic valve replacement
(AVR) because of risks arising from age and comorbidities.1
This observation stimulated the development of less-
invasive transcatheter aortic valve (TAV) procedures. It was
believed that TAV procedures would be associatedwith lower
mortality and morbidity compared with surgical AVR in el-
derly patients. However, TAV procedures have the potential
for serious complications related to the transcatheter place-ardiac Surgery,a Cardiology,b and Cardiovascular Anesthesiology,c Depart-
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The Journal of Thoracic and Carment itself, such as vascular complications, aortic dissec-
tion/perforation, stroke, myocardial infarction, and major
ventricular tachyarrhythmia.1,2 Overall 30-day major
adverse cardiovascular and cerebral events range from 3%
to 35%.1 On the other hand, once in place, the stent-
mounted valves function well with low transvalvular gradi-
ents. Still, the fact that the TAV procedure does not allow
the removal of the stenosed native valve raises questions on
the stability of valve function over time.Also, the relationship
between the degree of calcification and the high incidence of
paravalvular leakage as it is observed after TAV placement
remains to be elucidated. These findings stimulated the
interest in an alternative development, that is, a collapsible,
stent-mounted aortic valve prosthesis that can be placed in
a sutureless fashion with a conventional surgical technique.3
Sutureless implantation of heart valves has a significant ad-
vantage over the classic technique of suturing the valve in
place, because it shortens the necessary aortic crossclamp
time and therefore also the myocardial ischemia time. This
technology includes a classic extracorporeal circulation,
crossclamping of the aorta and an aortotomy, allowing com-
plete removal of the diseased native valve. The Perceval S
(Sorin Biomedica Cardio Srl, Sallugia, Italy) bioprosthesis
is such a sutureless aortic valve constructed from bovine peri-
cardium and mounted in a Nitinol stent.3 This stent-mounted
valve can be compressed and positioned in a transluminal
valve delivery system. The valve can be delivered throughdiovascular Surgery c Volume 142, Number 6 1453
FIGURE 1. Perceval S sutureless bioprosthesis (Sorin Biomedica Cardio
Srl, Sallugia, Italy).
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
NYHA ¼ New York Heart Association
TAV ¼ transcatheter aortic valve
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Dthe open aorta after removal of the diseased valve. This study
reports the effect of sutureless implantation of the Perceval S
bioprosthesis on aortic crossclamp time at implantation, the
hemodynamic performance of these valves, and the clinical
outcome during early follow-up.
MATERIALS AND METHODS
Device and Implantation Technique
The Perceval S bioprosthesis is constructed from bovine pericardium
and is a modification of the Sorin Pericarbon valve (Sorin Biomedica
Cardio Srl). The valve is mounted in a Nitinol stent (Figure 1). This
stent-mounted valve can be compressed and positioned in a valve delivery
system. The delivery system loaded with the compressed stent-mounted
valve is guided to its correct position by sliding it over three 4/0 Prolene
sutures connected to the annulus. These guiding sutures are stitched
through the annulus, halfway between 2 commissures. They are removed
after placement of the valve. Once the delivery system is in position, the
stent is deployed by turning the release screw and leaving the valve in
place. The delivery system and the guiding sutures are removed. Then a bal-
loon is inserted in the valve and expanded during 30 seconds at a pressure of
approximately 3 atm. After visual control of the valve position and the cor-
onary ostia, the aorta is closed. Only valves of 2 sizes, nominal labels 21
and 23, covering annulus diameters ranging from 19 to 21 mm and 21 to
23 mm, respectively, were available at the time of the study.
Surgical Procedure
After amedian full sternotomy (one casewith partial upper sternotomy),
the patients were placed on cardiopulmonary bypass (CPB), cannulating
the ascending aorta and right atrium. The heart was vented through the right
upper pulmonary vein. When coronary bypass surgery was needed, cooling
was performed to 32C and the grafts were implanted using intermittent
aortic crossclamping. When vein grafts were used, the proximal anastomo-
sis was performed using tangential aortic clamping after completion of the
distal anastomoses (during reperfusion) and before the aortotomy. Carewas
taken to implant the proximal grafts distal from the sinotubular junction to
avoid interference with the valve-stent. When the distal (and proximal)
anastomoses were complete, the aorta was again crossclamped, retrograde
cold-blood cardioplegia was started, and a transverse aortotomy was
performed above the sinotubular junction (slightly higher than for a conven-
tional valve given the height of the stent). The diseased valve was com-
pletely removed, the annulus was sized, and the sutureless device was
implanted as described above. The aortotomy was closed, and the clamp
was removed. A case of isolated aortic valve replacement is shown in
Video 1.
Patients
Thirty-two patients entered the study between September 2007 and No-
vember 2009. Inclusion criteria were aortic valve stenosis; age more than
75 years; euroSCORE greater than 5; and candidate for a standard surgical
intervention with a biological prosthesis, an NYHA function class of III or
greater, and a small and calcified aortic root/annulus. Exclusion criteria
were multivalve lesion, dilatation/dissection of the ascending aorta, previ-
ous cardiac surgery, and an aortic valve annulus diameter less than 19 mm1454 The Journal of Thoracic and Cardiovascular Suror greater than 23mmby direct intraoperativemeasurement. The study was
approved by the ethics committee of the hospital. All patients gave written
informed consent. Detailed patient characteristics are listed in Table 1.
Postoperatively, all patients were given aspirin only, with a prophylactic
dose of low-molecular-weight heparin during hospitalization. Patients in
chronic atrial fibrillation were anticoagulated.
Follow-up
All patients underwent transthoracic echocardiography at discharge and
at 6 months and 12 months postoperatively, together with a complete
physical examination, electrocardiography registration, and blood sam-
pling. Echocardiography included the measurement of peak and mean
transvalvular gradients and effective orifice area. Regurgitation was visual-
ized by color Doppler and scored as 0¼ non-existing,1¼ trivial, 2¼mild,
3 ¼ moderate, or 4 ¼ severe.
Statistical Analysis
Data are expressed as mean  standard deviation or as proportions
where needed. In Tables 1 to 3, additional information is provided with
medians and ranges (given the small patient number). For the analysis of
blood element analysis over time, a linear mixed model was used with
time points as repeated measurements and patients as subjects.RESULTS
Intraoperative Findings
In all patients, the surgical procedure went well. Fifty
percent of the patients received coronary artery bypass
grafting (CABG). The average number of grafts was 2.1
per patient (range, 1–4). As described above, the distal anas-
tomoses were made first using intermittent aortic cross-
clamping at 32C. Thereafter, the aorta was crossclamped
for the sutureless placement of the valve. Mean duration
of aortic crossclamping needed for the AVR was 17.8 
6.2 minutes (median, 17 minutes). Mean total aortic cross-
clamp time, including the intermittent phases needed togery c December 2011
TABLE 1. Patient characteristics (n ¼ 32, median values and range;
proportions)
No. of patients 32 (female, 65%)
Age 78 (75–87)
euroSCORE (median) 9.99 (6.2–34.7)


























STS, Society of Thoracic Surgeons; BSA, body surface area; NYHA, New York Heart
Association; TIA, transient ischemic attack; EF, ejection fraction.
TABLE 2. Intraoperative data (median values and range; proportions)
Transesophageal measurements (mm)
Annulus 22 (18–25)
Sinus of Valsalva 33 (21–36)
Sinotubular junction 27 (19–32)
Size of Perceval S valve (Sorin Biomedica Cardio
Srl, Sallugia, Italy) used
21 mm 7/32
23 mm 25/32
Aortic crossclamp time (min)
For AVR 17 (12–34)
Total aortic crossclamp time, including intermittent
clamping for CABG
22 (17–51)
CPB time (min) 46 (24–120)
Isolated AVR 35 (24–54)
AVRþCABG 62 (40–120)
CABG, Coronary artery bypass grafting; CPB, cardiopulmonary bypass; AVR, aortic
valve replacement.
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minutes (median, 22 minutes), and mean CPB time was
54.2 25.4 minutes (median, 46 minutes) (Table 2). Wean-








Peak pressure gradient 22 (9–50) 18 (4–47) 19 (5–36)
Mean pressure gradient 11 (5–28) 10 (6–28) 9 (3–21)
Effective orifice area 1.5 (0.8–2.2) 1.2 (0.8–2.2) 1.3 (0.8–2.4)
Valvular regurgitation grade
Absent–trivial 25/32 25/31 21/25
Mild 7/32 5/31 4/25
Moderate 0 1/31* 0
Severe 0 0 0
Paravalvular regurgitation
grade
Absent–trivial 27/32 25/31 23/25
Mild 5/32 5/31 2/25
Moderate 0 1/31* 0
Severe 0 0 0
*One patient with acute bacterial endocarditis.Valve Hemodynamics
Before discharge (ie, 1 week to 10 days postopera-
tively), all patients underwent transthoracic echocardiogra-
phy. All valves functioned well, peak gradient was 23 mm
Hg, mean gradient was 12 mm Hg, and effective orifice
area was 1.5 cm2 (Table 3). The valves showed absent to
trivial (score, 0–1) paravalvular regurgitations in 27 of 32
patients and mild (score, 2) paravalvular regurgitation in
5 of 32 patients. Valvular regurgitation was absent to trivial
(score, 0–1) in 25 of 32 patients and mild (score, 2) in 7 of
32 patients. Table 3 summarizes all data, including medians
and ranges.
During follow-up (ie, at the 6-month and 1-year echocar-
diographic examinations), the gradients and effective
orifice area values remained stable and there was a tendency
in the regurgitation scores to shift from mild to absent-
trivial, except in 1 patient, in whom endocarditis with severeThe Journal of Thoracic and Car(score, 3/4) and valvular and paravalvular regurgitation de-
veloped. This patient successfully underwent reoperation.
All results are summarized in Table 3.Blood Analyses
Blood element analysis showed changes with time after
surgery (Table 4). At discharge, red blood cell count hemat-
ocrit, hemoglobin, and creatine kinase-MB were signifi-
cantly lower and white blood cell count was higher than
before surgery, but all these parameters recovered com-
pletely within the next months. At discharge, the values of
free plasma hemoglobin, haptoglobin, reticulocytes, and
platelets were not significantly different from those before
surgery (P> .05). Serum lactate dehydrogenase, on the
other hand, was elevated (P< .001). At 6 and 12 months
postoperatively, platelet count and haptoglobin decreaseddiovascular Surgery c Volume 142, Number 6 1455








(n ¼ 22) Time effect
Red blood cells (1012/L) 4.11  0.53 3.57  0.38* 4.22  0.81 4.16  0.42 P<.001
White blood cells (109/L) 8.18  4.43 9.89  5.11z 7.81  4.48 6.57  2.30 P ¼ .015
Hematocrit 37.8  4.7 33.2  3.6* 37.5  4.3 38.5  3.7 P<.001
Hemoglobin (g/dL) 12.1  1.7 10.5  1.0* 11.8  1.4 12.7  1.8 P<.001
Free plasma hemoglobin (mg/dL) 3.4  3.8 2.7  4.5 5.5  4.6 5.2  4.7 P ¼ NS
Haptoglobin (g/L) 2.1  2.1 1.8  1.0 0.9  0.8x 0.9  0.6x P<.001
Reticulocytes (109/L) 4.20  5.17 7.62  8.14 15.04  19.93y 11.86  15.52y P ¼ .007
Platelets (109/L) 241  61 249  127 175  64x 184  57x P<.001
Serum LDH (U/L) 428  113 747  205y 590  149x 584  194x P<.001
CK-MB (mg/L) 1.67  1.42 1.00  0.49* 1.68  1.10 1.55  1.40 P ¼ .004
LDH, Lactate dehydrogenase; CK-MB, creatine kinase-MB; NS, not significant. *Different from all other time points. yDifferent from preoperative value. zDifferent from
12-month value. xDifferent from preoperative and discharge values.
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nase were elevated (P< .001). The decrease in platelet
count was moderate and not observed in all patients: Eight
patients (25%) had platelet counts more than 200 109/L;
none of the patients had counts less than 100 109/L. All re-
sults from the blood analyses over time are listed in Table 4.
Clinical Outcome
Median follow-up duration was 15.8 months. One patient
(3%) required surgical revision for bleeding, and 4 patients
(12%) required pleural puncture for pleural effusion. Mean
hospital stay was 15 days (range, 4–30 days). Median inten-
sive care unit stay was 2 days. One patient required tempo-
rary renal dialysis during the intensive care unit stay. All 32
patients went home or were admitted to a rehabilitation cen-
ter in good condition. Between 6 and 12 months postopera-
tively, there were 3 deaths (2 with respiratory failure after
infection, 1 after gastrointestinal bleeding). Acute bacterial
endocarditis developed in 1 patient, who successfully un-
derwent reoperation after 6 months. In all patients except
1, cardiac rhythm remained essentially unaltered after the
sutureless valve replacement. A previously non-existing
atrioventricular block developed in 1 patient, who received
a permanent pacemaker implantation. None of the patients
experienced a thromboembolic or bleeding event during
follow-up. New York Heart Association (NYHA) function
class improved. Preoperatively, 97% of patients were in
NYHA class III and 3% of patients were in NYHA class
IV (Table 1). At 6 months postoperatively, 35% of patients
were in NYHA class I, 62% of patients were in NYHA class
II, and 3% of patients were in NYHA class III. At 1 year,
48% of patients were in NYHA class I, 48% of patients
were in NYHA class II, and 3% of patients were in
NYHA class III.
DISCUSSION
For symptomatic patients with severe aortic valve steno-
sis, open surgery for AVRwith the use of cardioplegic arrest
under CPB remains the golden standard. The actual tech-1456 The Journal of Thoracic and Cardiovascular Surnique carries an (unacceptably) high perioperative risk
only in elderly patients with multiple comorbidities. For
these patients, TAV procedures were developed on a compas-
sionate basis.4,5 Currently, TAV procedures have lost their
compassionate basis, and inoperable and ‘‘high-risk’’
candidates are recruited. TAV procedures still carry the risk
of several periprocedural complications that may be life-
threatening.1 Dislocation or embolization of the graft, aortic
rupture and dissection, and obstruction of coronary ostia are
all devastating complications. The majority of patients will
have perivalvular insufficiency after TAV, and the incidence
of atrioventricular block is high.1 The retrograde approach
via the femoral artery is associated with several vascular
complications. The antegrade transapical approach requires
intubation and thoracotomy with the risk of bleeding from
the apex of the heart.6 These possible complications of
the TAV technology justify the search for an alternative tech-
nique to safely replace the aortic valve in high-risk candi-
dates for open surgery. We know from previous studies that
the duration of aortic crossclamping and CPB are indepen-
dent predictors of survival after valve replacement and
combined valve operations with CABG.7 Therefore, a tech-
nology focused on shortening aortic crossclamp time and
consequently CPB time is mandatory. The sutureless im-
plantation technique, as implemented with the Perceval S
aortic valve, has the potential of shortening aortic cross-
clamp time. Our results show that it is possible to implant
a well-functioning sutureless stent-mounted valve in the aor-
tic position in less than 20 minutes of aortic crossclamping,
including complete removal of the diseased native valve
without jeopardizing valve function. The decalcification
that we performed is similar to what is done for other valves.
There is no need to be more aggressive or to leave calcium in
place.
Our study was not designed to prove the superiority of
a sutureless implantation over any other technique, such
as TAV or classic open AVR. We only describe the results
in terms of mortality, morbidity, and valve hemodynamics.
Operative mortality in our limited series of sutureless aorticgery c December 2011
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advanced age, all patients recovered from surgery. Perioper-
ative morbidity was low. Low cardiac output syndrome dur-
ing the postoperative phase or signs of renal failure did not
develop in any patient. Vascular complications did not de-
velop in any patient. On the basis of echocardiographic
measurements, short-term efficacy and hemodynamics of
the Perceval S bioprosthesis are good. However, to reliably
evaluate long-term outcomes of this bioprosthesis, follow-
up studies longer than 1 year are needed. Our finding of
a moderate decrease in platelet count at 6 and 12 months
postprocedure particularly requires closer investigation. It
is known that many artificial heart valves, mainly the me-
chanical variants, induce some degree of hemolysis without
leading to serious clinical problems. In some cases, severe
paravalvular leakage can give rise to more relevant hemoly-
sis. Although we did not observe moderate to severe para-
valvular or valvular regurgitation in our patients (except
for 1 patient in whom endocarditis developed), this mecha-
nism cannot be excluded in our series of Perceval S valves
to explain the long-lasting effects on blood element integ-
rity. We looked for a possible correlation between the de-
crease of platelets and the occurrence of paravalvular
leaks or to valve size, but neither seemed to be correlated
in this small cohort of patients. Also, it is known that other
stentless but not sutureless bioprostheses, such as the Solo
valve (Sorin Biomedica Cardio Srl), can induce thrombocy-
topenia in the first postoperative days.8 The mechanism has
never been elucidated, and, as in our actual study of the Per-
ceval S valve, the phenomenon has no detectable clinical
relevance.
The Perceval S is not the only sutureless valve design cur-
rently under investigation. Other types of sutureless valves
have been implanted clinically.9-11 However, mean aortic
crossclamp times in these studies were 39  15 minutes,9
55  11 minutes,10 and 70  23 minutes,11 all significantly
longer than the crossclamp times in our experience with
Perceval S. The durability of these sutureless valves is an-
other issue. None of the currently available transfemoral
or transapical heart valves have proven durability. These
implant procedures are still limited to a special population
of elderly and ill patients. Although it is known that biopros-
thesis durability is better in older patients, durability studies
are still mandatory. It will be tempting to extend the use ofThe Journal of Thoracic and Carthe Perceval S valve to the entire population of patients re-
quiring a bioprosthesis in the aortic position.
CONCLUSIONS
The Perceval S valve is an efficient and well-functioning
device that offers the advantage of considerably shortening
the duration of aortic crossclamping. Whether this will af-
fect mortality andmorbidity substantially in elderly patients
is debatable. One major advantage of this valve will be seen
in patients undergoing complex operations, such as con-
comitant mitral/tricuspid surgery and coronary revasculari-
zation, especially in compromised ventricles. Adequate
follow-up studies are required to reliably evaluate long-
term outcome.References
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